Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 3/20 | 0.34 |
| ▸ | NPY2R | P49146 | 4/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.31 |
| ▸ | MITF | O75030 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.31 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 2/20 | 0.30 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13321787 | 0.95 | CCNT1 (0.35) | CCNT1NPY2RCNR2ANO1MAPT | |
| SCHEMBL2079443 | 0.93 | FPR2 (0.32) | CCNT1ANO1MAPTENPP1 | |
| SCHEMBL2081557 | 0.91 | CCNT1 (0.34) | CCNT1NPY2RANO1MITFLMNA | |
| SCHEMBL13321788 | 0.91 | LMNA (0.34) | NPY2RMETANO1MITFLMNA | |
| SCHEMBL13353994 | 0.86 | CNR2 (0.33) | NPY2RCNR2ANO1LMNAMAPT | |
| SCHEMBL2080175 | 0.85 | DGAT2 (0.39) | CCNT1DGAT2 | |
| SCHEMBL13321789 | 0.84 | PDK1 (0.34) | ANO1MAPT | |
| SCHEMBL4070987 | 0.82 | P2RY1 (0.33) | ANO1LMNAMAPT | |
| SCHEMBL2079067 | 0.80 | ABL1 (0.34) | CCNT1MAPK1DGAT2CDK9 | |
| SCHEMBL2825730 | 0.75 | MAPK13 (0.38) | NPY2RCNR2LMNAMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334294-B2 | 4,8-diphenyl-polyazanaphthalene derivatives | ALMIRALL, S.A. (ES) | 2012-12-18 | — | — | US | disclosed |
| US-20100130517-A1 | NEW 4,8-DIPHENYL-POLYAZANAPHTHALENE DERIVATIVES | ALMIRALL, S.A. (ES) | 2010-05-27 | — | — | US | disclosed |
| WO-2008131922-A1 | NEW 4,8-DIPHENYL-POLYAZANAPHTHALENE DERIVATIVES | ALMIRALL, S.A. (ES) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130517-A1 | NEW 4,8-DIPHENYL-POLYAZANAPHTHALENE DERIVATIVES | MAPK8, MAPK4, MAP3K8 | CCNT1 469/4885NPY2R 4192/4885MET 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.